A real life, multicenter, observational study to evaluate safety and efficacy of the switch from alemtuzumab to ocrelizumab in MS patient with evidence of disease activity after two alemtuzumab courses: the italian experience
MULTIPLE SCLEROSIS JOURNAL（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined